Clinical trials: Tamoxifen
Breast Cancer
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to…
- Trial name
- NCT00291759
- Testing
- Tamoxifen, Anastrozole
- Where
- 52 sites in Austria
- Volunteers
- 3,858 people
- Sponsor
- AstraZeneca
Breast Neoplasms, Neoplasms, Hormone-dependent
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
The purpose of this study is to determine whether the first line combination hormonal therapy of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug…
- Trial name
- NCT00044291
- Testing
- atamestane, toremifene, letrozole
- Where
- 63 sites in United States, Canada and 2 more
- Volunteers
- 865 people
- Sponsor
- Intarcia Therapeutics
Breast Cancer
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
The purpose of this study was to assess the difference in disease-free survival between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued…
- Trial name
- NCT00286117
- Testing
- Anastrozole, Tamoxifen
- Where
- 25 sites in Italy
- Volunteers
- 448 people
- Sponsor
- AstraZeneca
Osteoporosis, Postmenopausal
2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
The primary purpose of the study is to compare 3 different osteoporosis therapies following one year of teriparatide.In the first year,all eligible patients received open-label teriparatide 20 micrograms/day.After 1 year…
- Trial name
- NCT00191425
- Testing
- Teriparatide, Raloxifene
- Where
- Germany
- Volunteers
- 810 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003680
- Testing
- CMF regimen, cyclophosphamide, fluorouracil
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Scottish Cancer Therapy Network
Breast Cancer
Biologic Correlative Taxotere/AC
We are asking you to take part in a research study of biomarkers (characteristics or traits of the genes inside cancer cells). We want to learn if these biomarkers could help us learn how well your breast cancer may respond…
- Trial name
- TAX/AC (NCT00206466)
- Testing
- Taxotere, Adriamycin/cytoxan
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Baylor Breast Care Center
Osteopenia
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen, a drug already registered for prevention and treatment of…
- Trial name
- NCT00310531
- Testing
- Menostar (Estradiol, BAY86-5435), Raloxifene
- Volunteers
- 500 people
- Sponsor
- Bayer
Glioma
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
This study will determine whether the drugs tamoxifen and bortezomib can delay tumor growth in patients with recurrent glioma (malignant brain tumor).
- Trial name
- NCT00108069
- Testing
- Tamoxifen citrate, Bortezomib
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic Luminal B2 breast cancer subtype randomised to treatment with Trastuzumab Combined With Chemotherapy or Endocrine…
- Trial name
- SYSUCC-002 (NCT01950182)
- Testing
- Endocrine therapy combined with trastuzumab, Chemotherapy combined with trastuzumab
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Sun Yat-sen University
Breast Cancer Female
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
This clinical trial is designed to be a multi-center prospective, parallel-controlled Phase III clinical study. In this study, the efficacy of tamoxifen versus toremifene shall be compared in CYP2D6 intermediate/poor metabolizers…
- Trial name
- NCT03351062
- Testing
- Tamoxifen, Toremifene
- Where
- 21 sites in China
- Volunteers
- 844 people
- Sponsor
- Chinese Anti-Cancer Association
Breast Cancer, Hyposexual Desire Disorder
A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors
The purpose of this study is to determine if it is feasible for women to take both Flibanserin and tamoxifen for the duration of the study.
- Trial name
- NCT03707340
- Testing
- Flibanserin Pill
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
The long-term objective of this research is to understand the molecular mechanisms of acquired endocrine resistance in breast cancer.
- Trial name
- NCT00993642
- Testing
- Panobinostat (LBH589)
- Where
- United States
- Sponsor
- Tulane University Health Sciences Center
Breast Cancer
Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)
- Trial name
- NCT02995772
- Testing
- Aromatase Inhibitors (Arimidex), Tamoxifen, SOB
- Where
- Indonesia
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Dharmais National Cancer Center Hospital
Breast Neoplasms
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer.
- Trial name
- TEAM (NCT00036270)
- Testing
- exemestane (Aromasin), tamoxifen + exemestane
- Where
- 179 sites in United States
- Volunteers
- 9,779 people
- Sponsor
- Pfizer
Breast Cancer
Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer
The purpose of this study is to compare neo-adjuvant therapy of cytotoxic chemotherapy versus GnRHa with tamoxifen , of response rate(RR) in patients of hormone responsive and HER2 negative, lymph node positive, primary breast…
- Trial name
- NEST (NCT01622361)
- Testing
- Adriamycin+Cyclophosphamide>Docetaxel, GnRHa with Tamoxifen
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Asan Medical Center
Ductal Carcinoma in Situ, Extensive Disease
Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most…
- Conditions
- Ductal Carcinoma in Situ, Extensive Disease, Mastectomy
- Trial name
- HORNEO01 (NCT04666961)
- Testing
- Tamoxifen 20 mg, Anastrozole 1Mg Tab
- Where
- 8 sites in France
- Volunteers
- 262 people
- Sponsor
- Institut Cancerologie de l'Ouest
HER2/Neu Negative, Invasive Breast Carcinoma
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
This pilot clinical trial studies how well endocrine therapy works in treating patients with HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells.
- Conditions
- HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer
- Trial name
- NCT03238703
- Testing
- Anastrozole, Exemestane, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer, Estrogen Receptor Positive Tumor
Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients
Aim of this study is to characterize the chemical/physical and structural parameters of the skin in patients with breast cancer undergoing oncological adjuvant treatment in order to understand how to prevent and manage adverse…
- Trial name
- NCT06474988
- Testing
- Skin tests
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Institute of Oncology
Breast Cancer
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
The purpose of this project is to establish a repository of information and samples from breast cancer patients or those at high risk of developing breast cancer, who are initiating hormone therapy as part of standard clinical…
- Trial name
- NCT01937052
- Testing
- Sample collection, Patient-reported outcomes
- Where
- United States
- Volunteers
- 329 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Breast Neoplasms
Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country
This study evaluates the feasibility and efficacy of neoadjuvant tamoxifen for patients with locally advanced hormone receptor positive breast cancer in a low/middle income country.
- Trial name
- NCT02806544
- Testing
- Tamoxifen
- Volunteers
- 35 people
- Sponsor
- Vanderbilt University